Acute Liver Failure: V4 Gold Standard Guide

1. Summary

Acute Liver Failure (ALF) is a rare but catastrophic clinical syndrome defined by the rapid onset of hepatocellular dysfunction, specifically coagulopathy (INR ≥1.5) and hepatic encephalopathy, in a patient without pre-existing cirrhosis. [1] The process must occur within 26 weeks of the first symptoms (usually jaundice). [2] The central pathophysiology involves massive hepatocyte necrosis or severe metabolic dysfunction, leading to a total collapse of the liver's synthetic, metabolic, and excretory functions. [3] In the Western world, Paracetamol (Acetaminophen) toxicity is the most common cause, while viral hepatitis (A, B, E) predominates globally. [4] Mortality is primarily driven by Cerebral Oedema (intracranial hypertension) and multi-organ failure. [5] Early identification and immediate transfer to a specialized Liver Transplant Unit are critical, as emergency liver transplantation (ELT) remains the only life-saving intervention for patients meeting the King's College Criteria. [1,6]

2. Key Facts

• The Definition Triad: 1. Acute onset (less than 26 weeks), 2. Coagulopathy (INR ≥1.5), 3. Encephalopathy. [1]
• The "Killer" Mechanism: Cerebral oedema leading to brainstem herniation is the most common cause of early death in hyperacute ALF. [5,17]
• Paracetamol Prognosis: While paracetamol causes the most severe initial necrosis, it has a higher spontaneous recovery rate compared to drug-induced liver injury (DILI) if supported through the acute phase. [3,12]
• Metabolic Crisis: ALF is a state of profound Hypoglycaemia (loss of glycogen stores/gluconeogenesis) and Hyperammonaemia (failure of the urea cycle). [7,17]
• The Coagulopathy Trap: Do NOT correct INR with Fresh Frozen Plasma (FFP) unless the patient is actively bleeding or undergoing an invasive procedure. FFP masks the trend of the INR, which is the most sensitive marker of liver recovery or decline. [1,11]
• NAC for All: N-Acetylcysteine (NAC) improves transplant-free survival in non-paracetamol ALF (early stages) by improving microcirculatory flow and systemic oxygen delivery. [8]
• Coombs-Negative Warning: ALF + Coombs-negative haemolytic anaemia + low ALP/Bilirubin ratio = Wilson's Disease until proven otherwise. [15]

3. Clinical Pearls

The O'Grady Rule: Patients with Hyperacute failure (jaundice-to-coma less than 7 days) are the most likely to develop brain swelling but also the most likely to recover their liver function spontaneously. Conversely, Subacute patients (21 days–26 weeks) rarely swell but almost always die without a transplant. [2]

The "Shrinking Liver": A liver that is getting smaller on daily physical exam (shrinking liver span) during ALF is a sign of massive hepatocyte loss and liquefaction—a grave prognostic sign even if the ALT appears to be "improving." [1]

The "Wet brain" Check: In Grade 3/4 encephalopathy, sudden hypertension, bradycardia, or pupillary changes are not just "signs"—they are an emergency requiring immediate osmotic therapy (Mannitol) for brain herniation. [4,17]

The Ammonia Threshold: An arterial ammonia level > 150-200 µmol/L is a powerful predictor of intracranial hypertension. If you see this level, the patient belongs in a neuro-intensive care environment. [17]

4. Epidemiology

• Global Incidence: Rare, affecting ~1-6 per million people per year. [11]
• Aetiological Shifts: In the UK/US, paracetamol accounts for > 50% of cases. In Asia/Africa, Hepatitis B and E are the leading causes. [1,4]
• Mortality Evolution: Spontaneous survival has increased from 15% in the 1970s to ~45% today due to improved ICU care. Survival after emergency transplant is > 80% at 1 year. [1,12]
• Pregnancy Risk: Hepatitis E carries a 20-25% mortality rate in pregnant women in endemic areas, often presenting as ALF in the third trimester. [13]
• Age Profile: Typically affects young adults (mean age ~35-40), representing a massive loss of "productive life years." [11]

5. 7-Step Molecular Pathophysiology

Step 1: The Initial Insult (Necrosis vs. Apoptosis)

The trigger (toxic, viral, or ischaemic) causes massive cell death. In Paracetamol toxicity, NAPQI (toxic metabolite) binds to mitochondrial proteins, causing a burst of reactive oxygen species (ROS) and collapse of the mitochondrial membrane potential. In Viral/Autoimmune ALF, Fas-ligand and TNF-α trigger massive "explosive" apoptosis. [3,16]

Step 2: The Metabolic Collapse

As > 80% of hepatocytes fail, the liver's metabolic factory shuts down. Gluconeogenesis fails, leading to profound hypoglycaemia. The Urea Cycle collapses, leading to rising systemic Ammonia. Lactate clearance stops, contributing to profound Type B Lactic Acidosis. [7,17]

Step 3: The Ammonia-Glutamine Axis (Cerebral Oedema)

Ammonia crosses the blood-brain barrier. In the brain, astrocytes are the only cells that can detoxify ammonia, which they do by combining it with glutamate to form Glutamine. Glutamine acts as an osmolyte, drawing water into the astrocytes (cytotoxic oedema). [17]

Step 4: Systemic Vasodilation (The "SIRS" Surge)

Massive hepatocellular necrosis releases "Damage-Associated Molecular Patterns" (DAMPs) into the blood. This triggers a systemic inflammatory response syndrome (SIRS) even in the absence of infection. Massive Nitric Oxide release causes profound peripheral vasodilation (low SVR), mimicking septic shock. [22]

Step 5: The Cardiorenal Collapse (Type 1 HRS)

Systemic vasodilation leads to compensatory activation of the RAAS and sympathetic nervous system. This causes extreme renal vasoconstriction. Combined with direct toxic effects of DAMPs on the renal tubules, this leads to Type 1 Hepatorenal Syndrome (HRS-AKI) in 50-70% of ALF cases. [18]

Step 6: Coagulation "Reset"

The liver stops producing clotting factors (II, VII, IX, X) and natural anticoagulants (Protein C/S, Antithrombin III). While the INR rises (synthetic failure), the patient is in a precarious "rebalanced" state; they are at risk of both bleeding (low factors) and thrombosis (low anticoagulants). [1,11]

Step 7: Multi-Organ Dysfunction Syndrome (MODS)

The combination of cytokine storm, hyperammonaemia, and microvascular shunting leads to failure of the lungs (ARDS), heart (myocardial depression), and bone marrow (thrombocytopenia), creating the "Lethal Diamond" of ALF. [1]

6. Clinical Presentation

O'Grady Classification of ALF

Encephalopathy Grading (West Haven Criteria)

• Grade 1: Euphoria or anxiety, shortened attention span, impaired addition/subtraction.
• Grade 2: Lethargy, disorientation (time), obvious personality change, inappropriate behavior, Asterixis (flap).
• Grade 3: Somnolence to semi-stupor, responsive to verbal stimuli, gross disorientation, confused.
• Grade 4: Coma (unresponsive to verbal/painful stimuli). [19]

Differential Diagnosis (The "Mimics")

• Acute-on-Chronic Liver Failure (ACLF): Patient has pre-existing cirrhosis (look for stigmata like spider naevi, splenomegaly).
• Budd-Chiari Syndrome: Acute hepatic vein thrombosis (presents with painful hepatomegaly and ascites).
• Amanita Phalloides (Death Cap): History of mushroom foraging; severe GI phase followed by ALF.
• Herpes Simplex Virus (HSV): High fever, minimal jaundice, "punched out" necrosis on biopsy. Needs Aciclovir.

---

7. Special Populations

1. Pregnancy & Hepatitis E

Hepatitis E (HEV) is the leading cause of ALF in pregnant women in endemic areas.

• Pathophysiology: Severe immune-mediated damage combined with high viral loads.
• Outcome: 20-25% maternal mortality; high risk of vertical transmission and fetal loss. [13]
• Note: HEV genotype 1/2 are water-borne; genotype 3 is zoonotic (undercooked pork) and rarely causes ALF in pregnancy but can in the elderly.

2. Wilson's Disease (Acute Presentation)

A rare, usually fatal presentation of Wilson's.

• The Diagnostic Triad:
  1. Coombs-negative haemolytic anaemia (copper-induced RBC damage).
  2. Low ALP/Bilirubin ratio (less than 4).
  3. High urinary copper. [15]
• Prognosis: Almost 100% mortality without emergency liver transplant.

3. Amanita Phalloides (Mushroom Poisoning)

• Clinical Course:
  1. Latent period (6-12h).
  2. GI phase (severe cholera-like diarrhoea).
  3. Apparent recovery (24-48h).
  4. Massive hepatic necrosis (Day 3-4).
• Management: Silibinin (legalized in some regions), Penicillin G (blocks uptake), and emergency transplant.

---

8. Physical Exam (with Metrics)

The "ALF Bedside Mini-Exam":

1. Neurological: Check for orientation, flap, and pupillary symmetry.
2. Abdominal: Percuss the liver span (normal 6-12 cm). Palpate for the "tender liver" of Budd-Chiari.
3. Invasive lines: Check for oozing from puncture sites (DIC/Synthetic failure).

---

9. Investigations

1. The "Immediate" Liver Screen

• INR: Serial monitoring (every 6-12h).
• ALT/AST: Often > 5000 in Paracetamol/Ischaemia; less than 500 in Subacute ALF.
• Glucose: Finger-prick and lab (every 2h initially).
• Arterial Lactate: Powerful prognostic marker. [5]
• Arterial Ammonia: Predictor of ICP risk (> 150 µmol/L). [17]
• Paracetamol Level: Mandatory in ALL cases of ALF.
• Viral Serology: HAV IgM, HBV sAg, Anti-HBc IgM, HEV IgM/PCR, HSV/CMV PCR.
• Autoimmune: ANA, ASMA, IgG levels.
• Ceruloplasmin/Urinary Copper: If Wilson's suspected.

2. Imaging

• Abdominal US + Doppler: Rule out Budd-Chiari (hepatic vein patency) and cirrhosis.
• CT Head: Mandatory in Grade 3/4 encephalopathy to rule out ICH and assess for oedema before transplant or ICP monitor placement. [20]
• Chest X-ray: Rule out ARDS/Infection.

3. Invasive Monitoring

• Intracranial Pressure (ICP) Monitor: Controversial; used in some centers for Grade 3/4 ALF to guide osmotic therapy. High risk of ICH during placement. [1,4]

---

10. Management: The Gold Standard Algorithm

ASCII Management Flowchart (The "ALF Stabilization" Protocol)

                  [SUSPECTED ALF (INR > 1.5 + Altered Mental State)]
                                         |
                +------------------------v------------------------+
                |    EMERGENCY STABILISATION (ABC, Glucose)       |
                |    EMPIRICAL NAC (100mg/kg/day infusion)        |
                |    CONTACT TRANSPLANT CENTER IMMEDIATELY        |
                +------------------------+------------------------+
                                         |
                /------------------------+------------------------\
        [GRADE 1-2 ENCEPH.]                              [GRADE 3-4 ENCEPH.]
               |                                                |
        +------v------+                                  +------v------+
        | Ward/HDU    |                                  | ICU - INTUBATE|
        | Frequent Neu|                                  | Head Up 30 deg|
        | Obs         |                                  | Target Na 145 |
        +------+------+                                  +------+------+
               |                                                |
        /------+------\                                  /------+------\
    [MEETS KCC?]   [NO]                              [MEETS KCC?]    [NO]
           |        |                                      |        |
    +------v------+ |                               +------v------+ |
    | SUPER-URGENT| |                               | SUPER-URGENT| |
    | TRANSPLANT  | |                               | TRANSPLANT  | |
    | LISTING     | |                               | LISTING     | |
    +-------------+ |                               +-------------+ |
           ^--------+                                      ^--------+
                   |                                                |
           +-------v------------------------------------------------v-------+
           | SUPPORTIVE CARE:                                               |
           | - Renal: Early CRRT (Target Urea less than 10, clear Ammonia)           |
           | - Sepsis: Empirical broad-spectrum Abx/Antifungals             |
           | - Nutrition: Early enteral (Standard protein is SAFE)          |
           +----------------------------------------------------------------+

1. Specific Treatment: N-Acetylcysteine (NAC)

• Mechanism: Replenishes glutathione (in Paracetamol) and improves microcirculatory oxygen delivery (in non-paracetamol). [8]
• Dose: SNAP regimen for paracetamol; 100-150 mg/kg/day continuous infusion for non-paracetamol ALF until recovery or transplant.

2. Neurological Management (The "Anti-Oedema" Bundle)

• Intubation: Grade 3/4 encephalopathy (airway protection and pCO2 control).
• Positioning: Head of bed to 30 degrees (improves venous return).
• Osmotic Therapy: Mannitol (0.5-1.0 g/kg) or Hypertonic Saline (3% NaCl) for ICP spikes.
• Sodium Target: Maintain serum Sodium 145-150 mmol/L (prophylactic hypernatraemia reduces brain swelling). [1]

3. Renal & Metabolic Management

• Hypoglycaemia: Continuous 10-20% Dextrose infusion.
• CRRT (Dialysis): Start early. Aim is to clear ammonia and lactate, and maintain temperature. Do NOT wait for typical AKI indications. [1,18]
• PPI Prophylaxis: Mandatory to prevent stress ulcer bleeding.

4. Coagulation Management

• FFP/Cryo: Only for active bleeding or prior to procedures (e.g., ICP monitor placement).
• VTE Prophylaxis: Mechanical (SCDs) preferred; pharmacological is usually contraindicated due to INR.

---

11. Prognostic Criteria: The King's College Criteria (KCC)

The KCC is the global standard for emergency liver transplant listing. [5]

Paracetamol-Induced ALF

List for transplant if:

• Arterial pH less than 7.30 after fluid resuscitation.
• OR the triad of:
  1. Encephalopathy Grade 3 or 4.
  2. Prothrombin Time > 100 seconds (INR > 6.5).
  3. Serum Creatinine > 300 µmol/L.

Non-Paracetamol ALF

List for transplant if:

• INR > 6.5
• OR any three of the following:
  1. Age less than 10 or > 40 years.
  2. Aetiology (Non-A/Non-B hepatitis, DILI, Unknown).
  3. Duration of jaundice-to-encephalopathy > 7 days.
  4. INR > 3.5.
  5. Serum Bilirubin > 300 µmol/L.

---

12. Advanced Therapies: The Evidence Base

1. High-Volume Plasmapheresis (HVP)

The HVP Trial (Larsen et al., 2016) showed that exchanging 15% of body weight plasma over 3 days improves transplant-free survival (58.7% vs 47.8%). [23]

• Mechanism: Removes DAMPs, cytokines, and ammonia while replenishing coagulation factors.

2. Targeted Temperature Management (TTM)

Hypothermia (33-35°C) was traditionally used to reduce ICP. However, the FACT Trial showed no survival benefit for prophylactic hypothermia. Current guidelines recommend Rigorous Normothermia (avoiding fever). [24]

3. Bioartificial Livers (BAL)

Devices using porcine or human hepatoma cells. Despite many trials, NO BAL device has shown a mortality benefit in RCTs. They are NOT currently recommended. [1]

---

13. Complications & Multi-Organ Failure

---

14. Palliative Care in ALF

ALF has a rapid trajectory. If a patient is ineligible for transplant (e.g., severe multi-organ failure, advanced malignancy, uncontrolled infection):

• Withdrawal of Support: Often occurs when coning is imminent or multi-organ failure is irreversible.
• Symptom Control: Midazolam/Morphine for air hunger or agitation.
• Family Support: Critical, as the "healthy to dying" transition happens in days.

---

15. Single Best Answer (SBA) Questions

Question 1: The Paracetamol Pivot

A 22-year-old female presents with paracetamol overdose. Arterial pH is 7.28 after 2L of saline. INR is 4.0, Creatinine is 180, and she is Grade 2 confused. What is the most appropriate next step?

• A) Continue SNAP regimen and re-check in 4h.
• B) Refer to the Liver Transplant team for super-urgent listing.
• C) Give 4 units of FFP to correct the INR.
• D) Start CRRT for lactate clearance.
• E) Perform CT head to rule out oedema.
• Answer: B. According to KCC, an arterial pH less than 7.30 after fluid resuscitation in paracetamol ALF is an immediate indication for transplant listing, regardless of other parameters. [5]

Question 2: The Ammonia Threshold

A patient with Hep B ALF has an arterial ammonia of 185 µmol/L. He is Grade 2 encephalopathic. What is he at highest risk for?

• A) Fulminant sepsis.
• B) Acute tubular necrosis.
• C) Intracranial hypertension and cerebral oedema.
• D) GI haemorrhage.
• E) Hepatic vein thrombosis.
• Answer: C. Arterial ammonia > 150 µmol/L is a strong predictor for the development of intracranial hypertension in ALF. [17]

Question 3: The Subacute Trap

A 45-year-old male with an unknown cause of ALF has been jaundiced for 4 weeks before developing Grade 1 encephalopathy. INR is 2.5, Bilirubin 500, ALT 250. What is his likely outcome?

• A) 80% chance of spontaneous recovery.
• B) High risk of brain herniation in the next 24h.
• C) less than 10% chance of survival without transplant.
• D) Rapid recovery with NAC infusion.
• E) Spontaneous recovery after treating with corticosteroids.
• Answer: C. This is Subacute ALF. These patients have a very low risk of brain swelling (compared to hyperacute) but an extremely poor spontaneous survival rate (less than 10%). [2]

Question 4: The Electrolyte Target

In a patient with Grade 3 ALF, what is the recommended target for serum sodium to prevent cerebral oedema?

• A) 130 - 135 mmol/L.
• B) 135 - 140 mmol/L.
• C) 140 - 145 mmol/L.
• D) 145 - 150 mmol/L.
• E) > 155 mmol/L.
• Answer: D. Guidelines recommend prophylactic hypernatraemia (145-150 mmol/L) to create an osmotic gradient that pulls water out of the brain. [1]

Question 5: The Wilson's Clue

A 16-year-old girl presents with ALF. Bilirubin is 600, ALP is 50, Hb is 7.0 (Coombs negative). What is the next step?

• A) Start Prednisolone for Autoimmune Hepatitis.
• B) Emergency referral for liver transplant.
• C) Liver biopsy to confirm Wilson's.
• D) Start Penicillamine.
• E) High-dose NAC.
• Answer: B. Wilson's Disease presenting as ALF with haemolytic anaemia and low ALP/Bilirubin ratio is almost 100% fatal without a transplant. Biopsy is too dangerous due to INR. [15]

Question 6: The SNAP Regimen

What was the primary finding of the SNAP trial regarding NAC administration?

• A) It reduces mortality compared to the 21-hour regimen.
• B) It has a higher rate of anaphylactoid reactions.
• C) It is superior for non-paracetamol ALF.
• D) It significantly reduces nausea and vomiting compared to standard regimens.
• E) It should only be used in staggered overdoses.
• Answer: D. The SNAP 12-hour regimen was shown to have significantly fewer adverse effects (nausea/anaphylactoid) while remaining effective for paracetamol toxicity. [21]

Question 7: The "Shock Liver" Profile

A 60-year-old man is admitted post-VF arrest. ALT is 8000, INR 3.5, Bilirubin 40. LDH is 10,000. What is the diagnosis?

• A) Paracetamol toxicity.
• B) Acute Hepatitis B.
• C) Ischaemic Hepatitis (Shock Liver).
• D) Budd-Chiari Syndrome.
• E) Autoimmune Hepatitis.
• Answer: C. "Shock liver" is characterized by massive ALT/AST and LDH elevations with a relatively normal bilirubin, occurring 24-48h after a profound hypotensive event. [1]

Question 8: The CT Head timing

When is a CT head most indicated in ALF?

• A) In all patients with an INR > 2.0.
• B) Only if there are focal neurological signs.
• C) Prior to listing for transplant in a patient with Grade 3/4 encephalopathy.
• D) Every 12 hours to monitor for swelling.
• E) Never, as it doesn't change management.
• Answer: C. CT head is used to rule out intracranial haemorrhage (which might contraindicate transplant) and assess for established oedema in patients with deep coma. [4,20]

Question 9: The Renal Marker

Which lab value is used in the King's College Criteria for Paracetamol ALF but NOT for Non-Paracetamol ALF?

• A) Bilirubin.
• B) INR.
• C) Creatinine.
• D) Age.
• E) pH.
• Answer: C. Creatinine is a component of the KCC for Paracetamol (reflecting the severity of paracetamol-induced AKI) but is not part of the Non-Paracetamol criteria. [5]

Question 10: The HVP Benefit

According to the 2016 HVP trial, what was the primary benefit of High-Volume Plasmapheresis in ALF?

• A) It reduced the need for transplant.
• B) It improved transplant-free survival.
• C) It cleared paracetamol faster.
• D) It reduced the risk of fungal sepsis.
• E) It improved renal function.
• Answer: B. High-volume plasma exchange improved transplant-free survival by clearing toxins and modulating the inflammatory response. [23]

---

16. Landmark Trials Table

---

17. Layperson Explanation

Acute Liver Failure (ALF) is a rare and extreme emergency where a previously healthy liver stops working in a matter of days. Think of the liver as the body’s "central power plant" and "waste treatment facility." When it fails:

1. Waste Builds Up: Toxins like ammonia accumulate in the blood and travel to the brain, causing confusion or a coma (this is called encephalopathy).
2. Sugar Drops: The liver is responsible for releasing sugar into the blood; without it, the patient can have dangerously low blood sugar.
3. Clotting Stops: The patient loses the ability to clot blood, leading to a high risk of bleeding.

Most cases in the UK and USA are caused by an overdose of Paracetamol. The treatment involves being in an Intensive Care Unit (ICU) where machines (like a specialized dialysis machine) do the liver's work. If the liver doesn't show signs of healing within a few days, the patient is placed on a "Super-Urgent" transplant list to receive a new liver. The liver is the only organ that can grow back, so if we can support the patient through the crisis, they can often recover 100% function.

---

18. References

1. Bernal W, Wendon J. Acute Liver Failure. N Engl J Med. 2013;369(26):2525-34. [PMID: 24369077]
2. O'Grady JG, et al. Classification of acute liver failure. Lancet. 1993;342(8866):273-5. [PMID: 8101303]
3. Larson AM, et al. Acetaminophen-induced acute liver failure. Hepatology. 2005. [PMID: 16317692]
4. Bernal W, et al. Acute liver failure: A curable disease by 2024? J Hepatol. 2015. [PMID: 25920080]
5. O'Grady JG, et al. Early indicators of prognosis in fulminant hepatic failure (King's College Criteria). Gastroenterology. 1989. [PMID: 2490426]
6. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017. [PMID: 28412297]
7. Schiodt FV, et al. Glucose metabolism in acute liver failure. Hepatology. 1999. [PMID: 10474861]
8. Lee WM, et al. Intravenous N-acetylcysteine in non-acetaminophen ALF. Gastroenterology. 2009. [PMID: 19524577]
9. Michalopoulos GK. Liver regeneration. J Cell Physiol. 2007. [PMID: 17559071]
10. Clemmesen C, et al. Cerebral herniation and arterial ammonia in ALF. Hepatology. 1999. [PMID: 10051463]
11. Ostapowicz G, et al. ALF at 17 tertiary care centers in the US. Ann Intern Med. 2002. [PMID: 12484709]
12. Germani G, et al. Outcomes for patients with ALF listed for transplant. Transplantation. 2012. [PMID: 22179401]
13. Navaneethan U, et al. Viral hepatitis E and pregnancy. World J Gastroenterol. 2008. [PMID: 19009664]
14. Chalasani NP, et al. Features and Outcomes of DILI: The DILIN Study. Gastroenterology. 2015. [PMID: 25754159]
15. Korman JD, et al. Screening for Wilson disease in ALF. Hepatology. 2008. [PMID: 18821590]
16. Tujios SR, et al. ALF Resulting From Autoimmune Hepatitis. Hepatology. 2019. [PMID: 30044840]
17. Bernal W, et al. Arterial ammonia and clinical outcomes in ALF. Hepatology. 2007. [PMID: 17705260]
18. Betrosian AP, et al. Hepatorenal syndrome in ALF. World J Gastroenterol. 2007. [PMID: 17907287]
19. Vilstrup H, et al. Hepatic encephalopathy: AASLD/EASL Guidelines. Hepatology. 2014. [PMID: 25042402]
20. Wijdicks EF. Hepatic Encephalopathy. N Engl J Med. 2016. [PMID: 27783916]
21. Pettie JM, et al. The SNAP 12-hour acetylcysteine regimen. EClinicalMedicine. 2019. [PMID: 31193836]
22. Rolando N, et al. The SIRS in ALF. Hepatology. 2000. [PMID: 11003617]
23. Larsen FS, et al. High-volume plasma exchange in ALF. J Hepatol. 2016. [PMID: 26325537]
24. Karvellas CJ, et al. Targeted Temperature Management in ALF. Liver Transpl. 2015. [PMID: 26173001]

---

Last Updated: 2026-01-04 | MedVellum Editorial Team | Status: Gold Standard (V4)